
    
      Treatment-na√Øve patients with CUP diagnosis confirmed according to CUP Diagnostic Guidelines,
      will be enrolled into AGNOSTOS trial. Patients will be randomized upfront to receive a
      nab-paclitaxel-based duplet adding either carboplatin or gemcitabine until progression or
      unacceptable toxicity (randomization 1:1, n= 120; 60 per arm).
    
  